Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.

Abstract: Suppressive extracellular vesicles (EVs) such as PD-L1-bearing exosomes are produced by cancer cells and promote systemic suppression of the immune system, enabling tumors to escape immune surveillance. Inhibitors of suppressive EVs reduce the suppressive activity and/or the production of suppressive EVs, relieving systemic immunosuppression, and may be use to increase the efficacy of a co-administered immunotherapy. Additionally, engineered cancer cells that have an impaired capacity to produce PD-L1-bearing exosomes can be administered to prime the immune system against resident tumors, overcoming the systemic suppression of the immune system by cancer cells. Also, exogenously produced PD-L1-bearing exosomes may be administered to a subject for the treatment of an immune-related condition or to promote therapeutic immunosuppression.